TITLE

Earnings Roundup

PUB. DATE
July 2008
SOURCE
BioWorld Today;7/30/2008, Vol. 19 Issue 147, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decrease in the total revenue of QLT Inc. for the quarter ending June 30, 2008. The decrease was attributed to the drop in worldwide sales of age-related macular degeneration treatment Visudyne. The company reported a loss per share of 10 cents and ended the three-month period with about $120.9 million in cash and equivalents.
ACCESSION #
33404460

 

Related Articles

  • Regeneron's Revenues Nearly Triple; Eylea Launch Still Strong. Shaffer, Catherine // BioWorld Today;7/26/2012, Vol. 23 Issue 144, p1 

    The article reports that the revenues of Regeneron Pharmaceuticals Inc. have nearly tripled for the second quarter of 2012 amidst the strong launch of Eylea (aflibercept injection). The company has posted a total of 194 million U.S. dollars in sales and total revenues of 304 million U.S....

  • Treat-and-extend anti-VEGF regimen overtaking as-needed dosing.  // Ocular Surgery News;4/10/2012, Vol. 30 Issue 7, p22 

    The article discusses the findings of a study conducted by the Wills Eye Institute for patients dosing in Lucentis and Avastin medication which confirmed the efficacy of the treat-and-extend method in anti-Vascular Endothelial Growth factor (VEGF) treatment of wet age-related macular degeneration.

  • TargeGen Advances Topical AMD Program With $40M Series D. Boggs, Jennifer // BioWorld Today;7/16/2007, Vol. 18 Issue 136, p1 

    This article reports on the funding deal closed by TargeGen Inc. for the Phase II trial of its eye drop for treating age-related macular degeneration (AMD) and other back-of-the-eye diseases. Information is presented on the total amount of money raised by the firm since its founding in 2002. The...

  • Valeant Says 'Eye' to Buyout Of Visudyne: $112M for QLT. Osborne, Randy // BioWorld Today;9/25/2012, Vol. 23 Issue 186, p1 

    The article reports on QLT Inc.'s sale of its wet, age-related macular degeneration therapy, Visudyne, to Valeant Pharmaceuticals International Inc. Under the terms, QLT collected from Valeant 112.5 million U.S. dollars in cash. QLT also could receive as much as 5 million U.S. dollars in...

  • CIBA, QLT seek additional approvals.  // Ophthalmology Times;09/15/2000, Vol. 25 Issue 18, p67 

    Reports that CIBA Vision Corp. and QLT Inc. have filed a supplemental drug application for Visudyne therapy for the treatment of eye diseases beyond age-related macular degeneration (AMD). Comments from Luzi von Bidder, president of CIBA Vision's worldwide Ophthalmics Business unit; Basis of...

  • CLINIC ROUNDUP.  // BioWorld Today;3/31/2008, Vol. 19 Issue 62, p5 

    This section offers news briefs related to findings of clinical trials. Oral NR2B subtype selective methyl aspartate receptor antagonist were well tolerated in healthy young subjects, according to preliminary findings of Evotec AG. It outlines the results from a Phase II study of QLT Inc. of a...

  • Optherion's Protein Replacement For AMD Nabs $37M Series A. Morrison, Trista // BioWorld Today;10/10/2007, Vol. 18 Issue 197, p1 

    The article reports on the amount raised by New Haven, Connecticut-based Optherion Inc. from a Series A financing. The company raised $37 million to advance its preclinical research with a new approach to diagnosing and treating age-related macular degeneration (AMD). The company is pursuing the...

  • AGE RELATED MACULAR DEGENERATION. Jackson, Timothy L.; Kirkpatrick, Lucy // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/3/2011, Vol. 343 Issue 7821, p437 

    The article discusses an economic evaluation that compared the costs of bevacizumab and ranibizumab, drugs for treating wet age related macular degeneration (AMD), in Great Britain. The study estimates that switching to bevacizumab would save the country 556 million pounds over three years. It...

  • Avastin versus Lucentis. Godlee, Fiona // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/5/2012, Vol. 344 Issue 7855, preceding p1 

    An introduction is presented in which the editor-in-chief discusses articles within the issue on topics such as anti-vascular endothelial growth factors, manufacturers discouraging the use of anti-cancer drug, bevacizumab for macular degeneration.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics